Abstract 18882: Efficacy and Safety of Rivaroxaban in Patients with Peripheral Artery Disease: A GRADE-Assessed Systematic Review and Meta-Analysis
Abstract
Background: Peripheral artery disease (PAD) is a progressive atherosclerotic condition associated with high cardiovascular and limb-related morbidity. Despite guideline-recommended antiplatelet therapy, patients with PAD remain at substantial residual risk of ischemic and limb events. Rivaroxaban, a direct Factor Xa inhibitor, has emerged as a potential antithrombotic strategy, yet its net clinical benefit in PAD requires updated synthesis incorporating recent comparative data. Research Question: Does rivaroxaban-based therapy, alone or combined with aspirin, reduce cardiovascular, limb, and thromboembolic outcomes in patients with PAD without unacceptably increasing bleeding risk compared with placebo or standard antiplatelet therapy? Methods PubMed, Cochrane Library, and Embase were searched from inception to April 2026. Eligible studies enrolled PAD patients receiving rivaroxaban versus placebo, aspirin, dual antiplatelet therapy, warfarin, or apixaban. Risk ratios (RRs) and hazard ratios (HRs) with 95% CIs were pooled using random-effects models in R v4.5.1. Subgroup analyses compared rivaroxaban plus aspirin versus rivaroxaban alone. Risk of bias was assessed using RoB 2 and ROBINS-I; certainty of evidence was evaluated using GRADE. Results: Six studies comprising 39,991 participants were included. Rivaroxaban significantly reduced the composite efficacy outcome (RR 0.84, 95% CI 0.78-0.91), acute limb ischemia (RR 0.65, 95% CI 0.55-0.78), and thromboembolism (RR 0.60, 95% CI 0.38-0.97). No significant reductions were observed for stroke (RR 0.94, 95% CI 0.73-1.20), myocardial infarction (RR 0.87, 95% CI 0.73-1.04), all-cause mortality (RR 0.87, 95% CI 0.73-1.04), or cardiovascular mortality (RR 0.93, 95% CI 0.73-1.20). Amputation trended toward reduction but did not reach significance overall (RR 0.71, 95% CI 0.51-1.00); the rivaroxaban-alone subgroup showed a significant reduction (RR 0.50, 95% CI 0.30-0.85). Major bleeding was significantly increased (HR 1.54, 95% CI 1.41-1.69), as was ISTH-defined bleeding (RR 1.45, 95% CI 1.19-1.76); fatal bleeding was not significantly different. Conclusions: Rivaroxaban-based therapy reduces composite cardiovascular and limb outcomes and thromboembolism in PAD but significantly increases major bleeding without improving mortality, stroke, or myocardial infarction. These findings support individualized patient selection, with close attention to bleeding risk, when considering rivaroxaban in PAD management.